DON'T MISS A BEAT!
Every informative issue of Journal of Cardiovascular Pharmacology and Therapeutics (JCPT) offers cardiologists, clinical pharmacologists and researchers involved in disease relevant clinical and experimental investigations of newer cardiovascular drugs and other therapeutic options. Six times a year, JCPT examines and analyzes arenas such as:
- Agents that Reduce Myocardial Infarct Size
- Agents that Reduce Myocardial Remodeling
- Angiotensin Converting Enzyme Inhibitors
- Antihypertensive Therapy
- Atrial Fibrillation
- Beta-Blocker Therapies
- Cardioembolic Stroke
- Cardioprotective Agents
- Cardiopulmonary Resuscitation
- Cardiovascular Combination Therapies
- Chronic Angina
- Chronic Cardiac Ischemia
- Congestive Heart Failure
- Coronary Artery Disease
- Coronary Revascularization
- Heparin Therapies
- Implantable Devices
- Ischemic Heart Disease
- Myocardial Infarction
- Percutaneous Coronary Interventions
- Peripheral Arterial Disease
- Regenerative Cardiology
- Stem Cell Therapy
Among the drug classes regularly evaluated are: ACE inhibitors * angiotensin receptor blockers * anti-anginals * anti-arrhythmics * anti-coagulants * anti-hypertensives * anti-thrombins * beta-blockers * calcium channel blockers * cardioprotective agents * cardiotonic agents * direct renin inhibitors * diuretics * fibrinolytic agents * heart rate modulats * plasminogen activators * QT prolonging drugs * statins * vasoconstrictor agents * and vasodilator agents.
The journal features original articles, topical journal supplements, reviews, clinical and experimental investigations, and commentaries written by respected practitioners from all over the world.
This journal is a member of the Committee on Publication Ethics (COPE).
Journal of Cardiovascular Pharmacology and Therapeutics is a peer-reviewed journal that publishes original basic human studies, original animal studies, and original bench research with potential clinical application to cardiovascular pharmacology and therapeutics. The focus of the experimental studies is translational research. The journal also publishes review articles on basic research, clinical research, editorials, commentaries, points of view, and controversies. Selected journal supplements will also be published. Future focus will include cardioprotective therapies, stem cell therapy, regenerative cardiology, therapies for preventive cardiology (risk factor management), and antiarrhythmic therapies. Selected journal supplements will also be published.
|Karin Przyklenk, PhD||Director, Cardiovascular Research Institute; Professor, Physiology and Emergency Medicine, Wayne State University School of Medicine, Detroit, MI, USA|
|Amanda Bockman, BS||Los Angeles, CA, USA|
|Bruno K. Podesser, MD||Professor for Animal Research and Cardiac Surgery, Head Center for Biomedical Research, Medical University of Vienna, Austria|
|Richard S. Vander Heide, MD, PhD||Professor and Chair, Department of Pathology, Louisiana State University, New Orleans, LA, USA|
|Peter Whittaker, PhD||Professor, Department of Emergency Medicine, Wayne State University School of Medicine, Detroit, MI, USA|
|Bramah N. Singh, MD, DPhil, FRCP||UCLA School of Medicine, Los Angeles, CA, USA|
|Masanori Aikawa, PD, PhD||Harvard Medical School, Boston, MA, USA|
|Inder Anand, MD||University of Minnesota Medical School, Minneapolis, MN, USA|
|Jeffrey L. Anderson, MD, PhD||University of Utah School of Medicine, Salt Lake City, UT, USA|
|Ioanna Andreadou, PhD||National and Kapodistrian University of Athens, Athens, Greece|
|István Baczkó MD, PhD||University of Szeged, Szeged, Hungary|
|John E. Baker, PhD||Medical College of Wisconsin, Milwaukee, WI, USA|
|George Bakris, MD||The University of Chicago Medicine, Chicago, IL, USA|
|Gary Baxter, PhD||Cardiff University, Cardiff, Wales, UK|
|Anil Bhandari, MD||Keck School of Medicine, University of Southern California, Los Angeles, CA, USA|
|Deepak Bhatt, MD, MPH||Brigham and Women's Hospital, Boston, MA, USA|
|Yochai Birnbaum, MD||Baylor College of Medicine, Houston, TX, USA|
|William Boden, MD||Boston University School of Medicine, Harvard Medical School and VA New England Healthcare System, Boston, MA, USA|
|Hans Erik Botker, MD, PhD||University of Aarhus, Aarhus, Denmark|
|John Camm, MD, FRCP||St. George’s Hospital Medical School, London, UK|
|David Cannom, MD||Los Angeles Cardiology Associates, Los Angeles, CA, USA|
|Christopher Cannon, MD||Brigham and Women’s Hospital, Boston, MA, USA|
|Alassandro Capucci, MD||Università Politecnica delle Marche, Ancona, Italy|
|Bernard Chaitman, MD||St. Louis University, St. Louis, MO, USA|
|Harry J.G.M. Crijns, MD, PhD||Maastricht University Medical Center and CARIM, Maastricht, The Netherlands|
|Wangde Dai, MD||Huntington Medical Research Institutes, Pasadena, CA, USA|
|Marcelo DiCarli, MD||Brigham and Women’s Hospital, Boston, MA, USA|
|Yi Dong, MD, PhD||Indiana University School of Medicine, Indianapolis, IN, USA|
|James Downey, PhD||University of South Alabama, Mobile, AL, USA|
|Samuel Dudley, MD, PhD||University of Minnesota, Minneapolis, MN, USA|
|Dirk Duncker, MD, PhD||Erasmus University Medical Center Rotterdam, The Netherlands|
|Moses Elisaf, MD||University of Ioannina Medical School, Ioannina, Greece|
|Uri Elkayam, MD||Keck School of Medicine, University of Southern California, Los Angeles, CA, USA|
|Kathleen A. Fairman, MA||Midwestern University, Glendale, AZ, USA|
|Loren Field, PhD||Indiana University, Indianapolis, IN, USA|
|Stefan Frantz, MD, PhD||Medical Hospital I, University Hospital, Würzburg, Germany|
|Habib Gamra, MD||Fattouma Bourguiba University Hospital, Monastir, Tunisia|
|Candice Garwood, PharmD||Wayne State University, Detroit, MI, USA|
|Zoltan Giricz||Semmelweis University, Budapest, Hungary|
|Samuel Z. Goldhaber, MD||Brigham and Women’s Hospital, Boston, MA, USA|
|Thomas Gremmel, MD||Medical University of Vienna, Vienna, Austria|
|Gabriel B. Habib, MD||Baylor College of Medicine, Houston, TX, USA|
|Sharon Hale, BS||Huntington Medical Research Institutes, Pasadena, CA, USA|
|Gareth Hopkin, PhD||Institute of Health Economics & University of Alberta, Edmonton, AB, Canada|
|Daniel A. Jones, MD, PhD||Barts Heart Centre & Queen Mary University, London, UK|
|Attila Kiss, PhD||Medical University of Vienna, Vienna, Austria|
|Petra Kleinbongard, PhD||University of Essen Medical School, Germany|
|Robert A. Kloner, MD, PhD||Huntington Medical Research Institutes, Pasadena, CA, USA|
|John Kostis, MD||Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA|
|Cyrus R. Kumana, MBBS||University of Hong Kong, Hong Kong, China|
|Michael Laflamme, MD, PhD||University of Toronto, Toronto, ON, Canada|
|Richard A. Lange, MD||Texas Tech University Health Sciences Center, El Paso, TX, USA|
|Sandrine Lecour, PhD||University of Cape Town, Cape Town, South Africa|
|Jonathan Leor, MD||School of Medicine, Tel-Aviv University, Sheba Medical Center, Tel Hashomer, Israel|
|Matthew Linden, PhD||University of Western Australia, Perth, Australia|
|Joseph Loscalzo, MD, PhD||Brigham and Women’s Hospital, Boston, MA, USA|
|Douglas Losordo, MD||Caladrius Biosciences, Rye Brook, NY, USA|
|Jawahar Mehta, MD, PhD||University of Arkansas for Medical Sciences, Little Rock, AR, USA|
|Dimitri P. Mikhailidis, MD||Royal Free and University College Medical School, London, UK|
|Michael Miller, MD||University of Maryland, Baltimore, MD, USA|
|Tetsuji Miura, MD, PhD||Sapporo Medical University School of Medicine, Sapporo, Japan|
|Gerald Naccarelli, MD||Penn State College of Medicine, Hershey, PA, USA|
|Haruaki Nakaya, MD, PhD||Chiba University, Chiba, Japan|
|Michel Ovize, MD, PhD||Hospital Louis Pradel and Claude Bernard University, Lyon, France|
|Jason Peart, PhD||Griffith University, Brisbane, Queensland, Australia|
|Adam Perricone, MD, PhD||Emory University, Atlanta, GA, USA|
|J. Geoffrey Pickering, MD, PhD||Western University, London, ON, Canada|
|Fabrice Prunier, MD||University of Angers, Angers, France|
|Arshed A. Quyyumi, MD||Emory University School of Medicine, Atlanta, GA, USA|
|Thorsten Reffelmann, MD||Klinikum Mittelmosel, Zell an der Mosel, Germany|
|Shereif Rezkalla, MD||Marshfield Clinic, Marshfield, WI, USA|
|Clive Rosendorff, MD, PhD||Icahn School of Medicine at Mount Sinai, New York, James J. Peters VA Medical Center, Bronx, NY, USA|
|Fadi Salloum, PhD||Virginia Commonwealth University Medical Center, Richmond, VA, USA|
|Francesco Santoro, MD, PhD||University of Foggia, Foggia, Italy|
|Ernst R. Schwarz, MD, PhD||Cedars-Sinai Medical Center, Los Angeles, CA, USA|
|Prediman K. Shah, MD||Cedars-Sinai Medical Center, Los Angeles, CA, USA|
|David Shavelle, MD||Keck School of Medicine, University of Southern California, Los Angeles, CA, USA|
|Pawan K. Singal, PhD, DSc||University of Manitoba, Manitoba, Canada|
|Craig Smith, MD||University of Massachusetts Medical School, Worcester, MA, USA|
|James R. Sowers, MD||University of Missouri-Columbia School of Medicine, Columbia, MO, USA|
|Gregg W. Stone, MD||Columbia University Medical Center and New York Presbyterian Hospital, New York, NY, USA|
|Peter H. Stone, MD||Brigham and Women’s Hospital, Boston, MA, USA|
|John R. Teerlink, MD||University of California, San Francisco, CA, USA|
|Christopher Toombs, PhD||Proniras Corporation, Seattle, WA, USA|
|Paul M. Vanhoutte, MD, PhD||University of Hong Kong, Hong Kong, China|
|Orly Vardeny, PharmD||University of Minnesota Medical School, Minneapolis, MN, USA|
|Renu Virmani, MD||CVPath Institute, Inc., Gaithersburg, MD, USA|
|Michael A. Weber, MD||State University of New York Downstate College of Medicine, Brooklyn, NY, USA|
|Samuel Wickline, MD||University of South Florida, Tampa, FL, USA|
|Loren Wold, PhD||Ohio State University, Columbus, OH, USA|
|Derek M. Yellon, DSc||Hatter Cardiovascular Institute, University College London Hospital & Medical School, London, UK|
Please read the guidelines below then visit Journal of Cardiovascular Pharmacology and Therapeutics (JCPT)’s submission site at https://mc.manuscriptcentral.com/jcpat to upload your manuscript. Please note that manuscripts not conforming to these guidelines may be returned. Remember you can log in to the submission site at any time to check on the progress of your paper through the peer review process.
Only manuscripts of sufficient quality that meet the aims and scope of JCPT will be reviewed.
As part of the submission process you will be required to warrant that you are submitting your original work, that you have the rights in the work, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you, that you are submitting the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere. Please see our guidelines on prior publication and note that JCPT may accept submissions of papers that have been posted on pre-print servers; please alert the Editorial Office when submitting (contact details are at the end of these guidelines) and include the DOI for the preprint in the designated field in the manuscript submission system. Authors should not post an updated version of their paper on the preprint server while it is being peer reviewed for possible publication in the journal. If the article is accepted for publication, the author mayorcid re-use their work according to the journal's author archiving policy.
If your paper is accepted, you must include a link on your preprint to the final version of your paper.
This Journal is a member of the Committee on Publication Ethics.
This Journal recommends that authors follow the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals formulated by the International Committee of Medical Journal Editors (ICMJE).
There are no fees payable to submit or publish in this journal.
- What do we publish?
1.1 Aims & Scope
1.2 Article types
1.3 Writing your paper
1.3.1 Make your article discoverable
- Editorial policies
2.1 Peer review policy
2.3.1 Writing assistance
2.5 Declaration of conflicting interests
2.6 Research ethics and patient consent
2.7 Clinical trials
2.8 Reporting guidelines
2.9 Research data
- Publishing policies
3.1 Publication ethics
3.1.2 Prior publication
3.2 Contributor's publishing agreement
3.3 Open access and author archiving
- Preparing your manuscript for submission
4.2 Artwork, figures and other graphics
4.3 Supplemental material
4.4 Reference style
4.5 English language editing services
- Submitting your manuscript
5.2 Information required for completing your submission
- On acceptance and publication
6.1 SAGE Production
6.2 OnlineFirst publication
6.3 Access to your published article
6.4 Promoting your article
- Further information
7.1 Appealing the publication decision
Before submitting your manuscript to JCPT, please ensure you have read the Aims & Scope.
Journal of Cardiovascular Pharmacology and Therapeutics is a peer-reviewed journal that publishes original basic human studies, original animal studies, and original bench research with potential clinical application to cardiovascular pharmacology and therapeutics. The focus of the experimental studies is translational research. The journal also publishes review articles on basic research, clinical research, editorials, commentaries, points of view, and controversies. Selected journal supplements will also be published. Future focus will include cardioprotective therapies, stem cell therapy, regenerative cardiology, therapies for preventive cardiology (risk factor management), and antiarrhythmic therapies.
JCPT publishes both original clinical studies and original preclinical investigations with clear translational relevance. Areas of interest include (but are not limited to) cardioprotective therapies, stem cell therapy, regenerative cardiology, therapies for preventive cardiology (risk factor management), as well as antiplatelet, anticoagulation and antiarrhythmic therapies. The journal also welcomes the submission of timely and high-quality systematic reviews and meta-analyses focused on new and emerging cardiovascular therapies.
For preclinical investigation, priority will be given to in vivo studies that focus on pharmacologic therapy for disease models. In general isolated cell studies alone, without an in vivo component, will be given low priority. JCPT will not consider studies of herbal remedies: these contributions should be submitted to journals of alternative medicine.
Editorials, Commentaries and Letters to the Editor will be considered for publication on a highly selective basis. Case reports will not be accepted.
JCPT accepts the following article types:
- Original Manuscripts
- Manuscripts should be written clearly and concisely: maximum 6,000 words (including Abstract, Figure Legends and References)
- 200-250 word structured abstract
- 5-6 keywords
- Maximum 50 references
- Reviews should be written clearly and concisely: maximum 7,500 words (including Abstract, Figure Legends and References)
- 200-250 word structured abstract
- 5-6 keywords
- Maximum 100 references
- Letters to the Editor
- Letters are considered for publication on a highly selective basis, and must comment on a recent paper published in JCPT
- Letters reporting original data will not be accepted
- Maxium 1,000 words (including References)
- No abstract
- 3-4 keywords
- Maximum 5 references
The SAGE Author Gateway has some general advice and on how to get published, plus links to further resources.
For information and guidance on how to make your article more discoverable, visit our Gateway page on How to Help Readers Find Your Article Online.
JCPT operates a conventional single-blind reviewing policy in which the reviewer’s name is always concealed from the submitting author.
Decisions on manuscripts will be taken as rapidly as possible. In general, Editors will seek advice from two or more expert reviewers about the scientific content and presentation of submitted articles.
The Editor or members of the Editorial Board may occasionally submit their own manuscripts for possible publication in the journal. In these cases, the peer review process will be managed by alternative members of the Board and the submitting Editor/Board member will have no involvement in the decision-making process.
JCPT is committed to delivering high quality, fast peer-review for your paper, and as such has partnered with Publons. Publons is a third party service that seeks to track, verify and give credit for peer review. Reviewers for JCPT can opt in to Publons in order to claim their reviews or have them automatically verified and added to their reviewer profile. Reviewers claiming credit for their review will be associated with the relevant journal, but the article name, reviewer’s decision and the content of their review is not published on the site. For more information visit the Publons website.
Papers should only be submitted for consideration once all contributing authors give consent. Those submitting papers should carefully check that all those whose work contributed to the paper are acknowledged as contributing authors.
The list of authors should include all those who can legitimately claim authorship. This is all those who:
- Made a substantial contribution to the concept or design of the work; or acquisition, analysis or interpretation of data,
- Drafted the article or revised it critically for important intellectual content,
- Approved the version to be published,
- Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.
Authors should meet the conditions of all of the points above. When a large, multicenter group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. These individuals should fully meet the criteria for authorship.
Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship, although all contributors who do not meet the criteria for authorship should be listed in the Acknowledgments section. Please refer to the International Committee of Medical Journal Editors (ICMJE) authorship guidelines for more information on authorship.
All contributors who do not meet the criteria for authorship should be listed in an Acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, or a department chair who provided only general support.
Any acknowledgements should appear first at the end of your article prior to your Declaration of Conflicting Interests (if applicable), any notes and your References.
Individuals who provided writing assistance, e.g. from a specialist communications company, do not qualify as authors and so should be included in the Acknowledgements section. Authors must disclose any writing assistance – including the individual’s name, company and level of input – and identify the entity that paid for this assistance. It is not necessary to disclose use of language polishing services.
JCPT requires all authors to acknowledge their funding in a consistent fashion under a separate heading. Please visit the Funding Acknowledgements page on the SAGE Journal Author Gateway to confirm the format of the acknowledgment text in the event of funding, or state that: “This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.”
It is the policy of JCPT to require a declaration of conflicting interests from all authors enabling a statement to be carried within the paginated pages of all published articles.
Please ensure that a ‘Declaration of Conflicting Interests’ statement is included at the end of your manuscript, after any acknowledgements and prior to the references. If no conflict exists, please state that: “The Author(s) declare(s) that there is no conflict of interest.” For guidance on conflict of interest statements, please see the ICMJE recommendations here.
Medical research involving human subjects must be conducted according to the World Medical Association Declaration of Helsinki. A statement that the protocol and informed consent were reviewed and approved by an IRB (Institutional Review Board) should be included in the methods section.
Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, and all papers reporting animal and/or human studies must state in the methods section that the relevant Ethics Committee or Institutional Review Board provided (or waived) approval. Please ensure that you have provided the full name and institution of the review committee, in addition to the approval number.
For research articles, authors are also required to state in the methods section whether participants provided informed consent and whether the consent was written or verbal.
Information on informed consent to report individual cases or case series should be included in the manuscript text. A statement is required regarding whether written informed consent for patient information and images to be published was provided by the patient(s) or a legally authorized representative. Please do not submit the patient’s actual written informed consent with your article, as this in itself breaches the patient’s confidentiality. The Journal requests that you confirm to us, in writing, that you have obtained written informed consent but the written consent itself should be held by the authors/investigators themselves, for example in a patient’s hospital record. The confirmatory letter may be uploaded with your submission as a separate file.
Please also refer to the ICMJE Recommendations for the Protection of Research Participants.
All research involving animals submitted for publication must be approved by an ethics committee with oversight of the facility in which the studies were conducted. The journal has adopted the Consensus Author Guidelines on Animal Ethics and Welfare for Veterinary Journals published by the International Association of Veterinary Editors. A statement to this effect needs to be described in the methods section. In addition a statement that the protocol was approved by an IACUC (Institutional Animal Care and Use Committee) is required.
JCPT conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrollment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract. The registration number and registry name for clinical trials should be provided in the methods section.
The relevant EQUATOR Network reporting guidelines should be followed depending on the type of study. For example, all randomized controlled trials submitted for publication should include a completed CONSORT flow chart as a cited figure and the completed CONSORT checklist should be uploaded with your submission as a supplemental file. Systematic reviews and meta-analyses should include the completed PRISMA flow chart as a cited figure and the completed PRISMA checklist should be uploaded with your submission as a supplemental file. The EQUATOR wizard can help you identify the appropriate guideline.
Other resources can be found at NLM’s Research Reporting Guidelines and Initiatives.
At SAGE we are committed to facilitating openness, transparency and reproducibility of research. Where relevant, The Journal encourages authors to share their research data in a suitable public repository subject to ethical considerations and where data is included, to add a data accessibility statement in their manuscript file. Authors should also follow data citation principles. For more information please visit the SAGE Author Gateway, which includes information about SAGE’s partnership with the data repository figshare.
SAGE is committed to upholding the integrity of the academic record. We encourage authors to refer to the Committee on Publication Ethics’ International Standards for Authors and view the Publication Ethics page on the SAGE Author Gateway.
JCPT and SAGE take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of published articles. Equally, we seek to protect the reputation of the journal against malpractice. Submitted articles may be checked with duplication-checking software. Where an article, for example, is found to have plagiarized other work or included third-party copyright material without permission or with insufficient acknowledgement, or where the authorship of the article is contested, we reserve the right to take action including, but not limited to: publishing an erratum or corrigendum (correction); retracting the article; taking up the matter with the head of department or dean of the author's institution and/or relevant academic bodies or societies; or taking appropriate legal action.
In order to help assure that all manuscripts are original submitted papers are routinely screened using a computerize plagiarism tracking system known as iThenticate. This program identifies phrases, sentences, and paragraphs that have previously been published, including the authors' own work. The program generates a similarity index. If the similarity index is greater than ~33% after removal of the bibliography, the manuscript will be returned to the authors without a review.
If material has been previously published it is not generally acceptable for publication in a SAGE journal. However, there are certain circumstances where previously published material can be considered for publication. Please refer to the guidance on the SAGE Author Gateway or if in doubt, contact the Editor at the address given below.
Before publication, SAGE requires the author as the rights holder to sign a Journal Contributor’s Publishing Agreement. SAGE’s Journal Contributor’s Publishing Agreement is an exclusive licence agreement which means that the author retains copyright in the work but grants SAGE the sole and exclusive right and licence to publish for the full legal term of copyright. Exceptions may exist where an assignment of copyright is required or preferred by a proprietor other than SAGE. In this case copyright in the work will be assigned from the author to the society. For more information please visit the SAGE Author Gateway.
JCPT offers optional open access publishing via the SAGE Choice program. For more information please visit the SAGE Choice website. For information on funding body compliance, and depositing your article in repositories, please visit SAGE Publishing Policies on our Journal Author Gateway.
The preferred format for your manuscript is Word. Word templates are available on the Manuscript Submission Guidelines page of our Author Gateway.
Manuscripts are accepted for consideration on the condition that they are contributed solely to JCPT. No substantial part of a paper may have been published elsewhere, including being published in another language besides English, except as a scientific abstract. All work must be original. Previously published long phrases, sentences, and paragraphs (including the author’s own work) must be properly cited in AMA format—anything else will be considered unacceptable. A direct quote of no more than 4 lines from textual material should be enclosed in double quotation marks; if longer than 4 lines it should be formatted as a block extract. Always verify the quote against the original source, and the citation should include the exact page number(s) of the source. Such directly quoted material should be used sparingly. The receipt of your manuscript by the Journal will be acknowledged and a decision regarding its status made as soon as possible. All manuscripts are subject to editorial review. Manuscripts must be written in acceptable English. Manuscripts submitted in poor English will be returned without review. Some manuscripts that are deemed inappropriate for the journal or very low priority by the editorial staff may be returned without review.
The manuscript is to be accompanied by a cover letter that states (1) all the authors have read and approved the final manuscript, (2) all authors have read and approve of the data being presented in the manuscript, and (3) the full name, address, e-mail address, phone, and fax number of the individual to whom correspondence concerning the manuscript is to be sent. The cover letter must also specifically state and verify that the paper being submitted has not been previously published in whole or in part in any form, including being published in another language besides English, is not under consideration for publication elsewhere, and is original. The cover letter should be addressed to
Karin Przyklenk, PhD
Journal of Cardiovascular Pharmacology and Therapeutics
Wayne State University School of Medicine
On the title page, please include all of the following information:
- The names, degrees, and professional affiliation (position, department, institution, place) of all authors.
- The name of the institution where the work reported was done.
- Acknowledgment of grant support when appropriate.
- Complete mailing address, telephone, and fax of corresponding author and e-mail addresses of all authors.
The American Medical Association (AMA) Manual of Style, is the standard source of style. For more information on the AMA Manual of Style, please visit http://www.amamanualofstyle.com/.
The abstract should be no longer than 250 words in length. The abstract should summarize the main points of the paper and be descriptive, narrative, and informative and should include only information that is in the article. Avoid abbreviations. At the bottom of the abstract, please also submit a maximum of 5 keywords for your article.
Body of the Text
For most original manuscripts, the subheadings Introduction, Methods and Materials, Results, Discussion, and Conclusion or Summary are suggested. The introduction should be no longer than 2-3 paragraphs and should provide background and rationale for the study and specifically state the purpose of the study. The methods section should describe what statistical tests were used. The text of the paper should be no longer than 15-20 double-spaced typed pages in most cases. All tables and figures should be referenced in the main text in the order in which they appear. The discussion should stress what is new in the paper and relate the author’s findings to the existing literature. The discussion should show how the findings add to the existing knowledge base of the subject under study.
Please avoid excessive and unnecessary abbreviations. Keep them to a minimum. The first time an abbreviation is used it should be defined.
All tables must be cited in text. Tables are to be numbered with Arabic numerals (Table 1, Table 2) in order of their text citation. Each table should be typed (double-spaced throughout) on a separate sheet of paper and should have a title. Use spaces, not vertical rules, to separate columns. Each table should have a legend in sufficient detail to allow understanding without reference to the text.
For guidance on the preparation of illustrations, pictures and graphs in electronic format, please visit SAGE’s Manuscript Submission Guidelines.
Figures supplied in color will appear in color online regardless of whether or not these illustrations are reproduced in color in the printed version. Color figures for the print issue are charged to the author at the rate of $800 for the first figure and $200 for each subsequent figure. Payment must be received before the article can appear in print; the author should note his or her desire to have figures appear in color in the print issue when he or she submits his or her article.
Acceptable file formats include the following: TIFF, JPEG, and PDF. Microsoft application files are acceptable for vector art (line art).
Line art (black and white) images should be scanned as a bitmap at 900ppi. Photos should be scanned as grayscale or CMYK at 300ppi.
This journal is able to host additional materials online (e.g. datasets, podcasts, videos, images etc.) alongside the full-text of the article. For more information please refer to our guidelines on submitting supplemental files.
JCPT adheres to the AMA Manual of Style. View the guide here to ensure your manuscript conforms to this style.
In the text, please use a superscripted number that correlates with the reference at the end of the manuscript. When several references are cited simultaneously in the text, you can list the superscripted numbers together, for example, ‘‘Many researchers have debated this subject.1,2,5,9’’ Use ‘‘et al’’ for cites of 3 authors or more in text. However, in the references, list up to 6 authors. If there are more than 6 authors, list the first 3 authors and then ‘‘et al’’. Type references double-spaced at the end of the manuscript numbered in order of appearance in the manuscript. Unpublished data and personal communications should be given as references. Manuscripts in press may be referenced; however, manuscripts that have been submitted for publication but have not been accepted yet should not be referenced. Avoid quoting abstracts where possible.
Michaud G, McGowan JL, van der Jagt R, et al. Are therapeutic decisions supported by evidence from health care research? Arch Intern Med. 1998;158:1665-1668.
Cole BR. Cystinosis and cystinuria. In: Jacobson HR, Striker GE, Klahr S, eds. The Principles and Practice of Nephrology. Philadelphia, PA: BC Decker Inc; 1991:396-403.
Sackett DL, Straus SE, Richardson WS, et al. Evidence-based Medicine: How to Practice and Teach EBM. 2nd ed. New York, NY: Churchill Livingstone; 2000.
Authors seeking assistance with English language editing, translation, or figure and manuscript formatting to fit the journal’s specifications should consider using SAGE Language Services. Visit SAGE Language Services on our Journal Author Gateway for further information.
JCPT is hosted on SAGE Track, a web based online submission and peer review system powered by ScholarOne™ Manuscripts. Visit https://mc.manuscriptcentral.com/jcpat to login and submit your article online.
IMPORTANT: Please check whether you already have an account in the system before trying to create a new one. If you have reviewed or authored for the journal in the past year it is likely that you will have had an account created. For further guidance on submitting your manuscript online please visit ScholarOne Online Help.
As part of our commitment to ensuring an ethical, transparent and fair peer review process SAGE is a supporting member of ORCID, the Open Researcher and Contributor ID. ORCID provides a unique and persistent digital identifier that distinguishes researchers from every other researcher, even those who share the same name, and, through integration in key research workflows such as manuscript and grant submission, supports automated linkages between researchers and their professional activities, ensuring that their work is recognized.
The collection of ORCID IDs from corresponding authors is now part of the submission process of this journal. If you already have an ORCID ID you will be asked to associate that to your submission during the online submission process. We also strongly encourage all co-authors to link their ORCID ID to their accounts in our online peer review platforms. It takes seconds to do: click the link when prompted, sign into your ORCID account and our systems are automatically updated. Your ORCID ID will become part of your accepted publication’s metadata, making your work attributable to you and only you. Your ORCID ID is published with your article so that fellow researchers reading your work can link to your ORCID profile and from there link to your other publications.
You will be asked to provide contact details and academic affiliations for all co-authors via the submission system and identify who is to be the corresponding author. These details must match what appears on your manuscript. The affiliation listed in the manuscript should be the institution where the research was conducted. If an author has moved to a new institution since completing the research, the new affiliation can be included in a manuscript note at the end of the paper. At this stage please ensure you have included all the required statements and declarations and uploaded any additional supplemental files (including reporting guidelines where relevant).
Please also ensure that you have obtained any necessary permission from copyright holders for reproducing any illustrations, tables, figures or lengthy quotations previously published elsewhere. For further information including guidance on fair dealing for criticism and review, please see the Copyright and Permissions page on the SAGE Author Gateway.
Your SAGE Production Editor will keep you informed as to your article’s progress throughout the production process. Proofs will be made available to the corresponding author via our editing portal SAGE Edit or by email, and corrections should be made directly or notified to us promptly. Authors are reminded to check their proofs carefully to confirm that all author information, including names, affiliations, sequence and contact details are correct, and that Funding and Conflict of Interest statements, if any, are accurate. Please note that if there are any changes to the author list at this stage all authors will be required to complete and sign a form authorizing the change.
OnlineFirst allows final articles (completed and approved articles awaiting assignment to a future issue) to be published online prior to their inclusion in a journal issue, which significantly reduces the lead time between submission and publication. Visit the SAGE Journals help page for more details, including how to cite OnlineFirst articles.
SAGE provides authors with online access to their final article.
Publication is not the end of the process! You can help disseminate your paper and ensure it is as widely read and cited as possible. The SAGE Author Gateway has numerous resources to help you promote your work. Visit the Promote Your Article page on the Gateway for tips and advice. In addition, SAGE is partnered with Kudos, a free service that allows authors to explain, enrich, share, and measure the impact of their article. Find out how to maximize your article’s impact with Kudos.
Any correspondence, queries or additional requests for information on the manuscript submission process should be sent to the JCPT editorial office as follows:
Amanda Bockman, Managing Editor
Editors have very broad discretion in determining whether an article is an appropriate fit for their journal. Many manuscripts are declined with a very general statement of the rejection decision. These decisions are not eligible for formal appeal unless the author believes the decision to reject the manuscript was based on an error in the review of the article, in which case the author may appeal the decision by providing the Editor with a detailed written description of the error they believe occurred.
If an author believes the decision regarding their manuscript was affected by a publication ethics breach, the author may contact the publisher with a detailed written description of their concern, and information supporting the concern, at email@example.com.